Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cetilistat moves to Phase III in Japan

This article was originally published in Scrip

Executive Summary

Takedahas begun the Japanese Phase III development of Alizyme's pancreatic lipase inhibitor cetilistat (ATL-962). The formal start of the programme has triggered a $3 million milestone payment to the UK firm, which has now received $10 million under the licensing agreement and could receive up to a further $32 million before sales royalties. Takeda holds exclusive local rights for use in obesity and related disorders such as type 2 diabetes and dyslipidaemia and has already completed a Phase II trial in around 450 diabetic obese patients. This showed weight loss, glycaemic control and other benefits for cetilistat compared with placebo over a six-month treatment period.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007915

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel